



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 16/28, A61K 39/395, C12N 15/12	A1	(11) International Publication Number: WO 00/29445 (43) International Publication Date: 25 May 2000 (25.05.00)
<p>(21) International Application Number: PCT/KR99/00689</p> <p>(22) International Filing Date: 17 November 1999 (17.11.99)</p> <p>(30) Priority Data: 1998/49177 17 November 1998 (17.11.98) KR 1999/16750 11 May 1999 (11.05.99) KR</p> <p>(71) Applicant: LG CHEMICAL LIMITED [KR/KR]; #20, Yoido-dong, Yongdungpo-gu, Seoul 150-721 (KR).</p> <p>(72) Inventors: HONG, Hyo, Jeong; Kwagiwon Kyosu Apt. 15-401, #237, Kajeong-dong, Yuseong-gu, Daejeon 305-350 (KR). PARK, Sung, Sup; Hanbit Apt. 110-502, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). KANG, Young, Jun; Expo Apt. 106-802, Jeonmin-dong, Yuseong-gu, Daejeon 305-390 (KR). KANG, Chang, Yuil; Daewoo Hyoryeong Apt. 104-502, #1038, Bangbae-dong, Seocho-gu, Seoul 137-060 (KR). YOON, Sung, Kwan; Jindalrae Apt. 109-1003, #312-1, Seo-gu, Daejeon 302-280 (KR).</p> <p>(74) Agents: JANG, Seong, Ku et al.; KEC Building, 17th floor, #275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TC).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: HUMANIZED ANTIBODY SPECIFIC FOR HUMAN 4-1BB AND PHARMACEUTICAL COMPOSITION COMPRISING SAME</p> <p>(57) Abstract</p> <p>The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Humanized Antibody Specific for Human 4-1BB and
Pharmaceutical Composition Comprising Same**

Field of the Invention

The invention relates to humanized antibodies that specifically bind to 4-1BB receptor proteins, preferably to human 4-1BB receptor protein. The humanized
5 antibodies can be used as diagnostic reagents or can be formulated into pharmaceutical compositions for administration to a patient.

Background of the Invention

The immune system has tremendous diversity and
10 because the repertoire of specificities expressed by the B- and T-cell populations is generated randomly, it is bound to include many which are specific for self components. Thus, the body must establish self-tolerance mechanisms to distinguish between self and non-self
15 determinants so as to avoid autoreactivity. However, all mechanisms have a risk of breakdown. The self-recognition mechanisms are no exception, and a number of diseases have been identified in which there is autoimmunity due to copious production of autoantibodies and autoreactive T
20 cells.

There are at least 30 diseases which are either caused by or related to autoimmunity. Examples of such diseases include rheumatoid arthritis, pemphigus vulgaris, glomerulonephritis, pernicious anemia, thyroiditis and
25 systemic lupus erythematosus. In Korea, one person in one hundred suffers from rheumatoid arthritis.

The transplantation of tissues to replace diseased organs is now an important medical therapy. In most cases, adaptive immune responses to the grafted tissues are the

- 2 -

major impediment to successful transplantation. When tissues containing nucleated cells are transplanted, T-cell responses to the highly polymorphic MHC (major histocompatibility complex) molecules almost always trigger a response against the grafted organ. Matching the MHC type of donor and recipient increases the success rate of grafts, but perfect matching is possible only when donor and recipient are related and, in these cases, genetic differences at other loci still trigger rejection.

10 The immune system may be manipulated or controlled to suppress unwanted immune responses in autoimmune disease and graft rejection. Currently, several different immunosuppressive agents have been used clinically. The examples are methotrexate, azathiopurine, cyclophosphamide, 15 prednisone, cyclosporine A, FK506 (tacrolimus), anti-lymphocyte globulin (ALG) and anti-thymocyte globulin (ATG). Very recently, antibodies by virtue of their exquisite specificity have been utilized for the therapeutic inhibition of specific immune responses. The 20 target molecules for these antibodies can be divided into two groups. The first group includes molecules that are expressed on the surface of lymphocytes, such as CD3, CD4, IL-2R, CDw52 and ICAM-1. The other groups are mainly cytokines such as TNF- α and IL-6. Some of the antibodies 25 are effective and are being sold as pharmaceutical products.

 However, the presently developed immunosuppressants have a common problem in that cells that are not related to immune response or normal cells are all affected by the 30 drugs. This causes serious side effects that cannot be avoided. Therefore, an immunosuppressant is desired that is specific for activated immune cells, has excellent immunosuppressive activity, and has no adverse side effect.

- 3 -

Although murine monoclonal antibodies are extensively used as diagnostic agents, their utility as therapeutics has been proven in only a few cases. The limited application is attributed to three major reasons. First, the repeated administration of murine monoclonal antibodies to humans usually elicits human immune responses against these molecules. The human anti-mouse antibody (HAMA) responses are directed to two different domains. The responses against the variable region are so called anti-idiotypic responses which could block the antigen binding activity of murine antibodies. The responses against the constant region represent anti-isotype responses, which block the effector function of antibodies. The HAMA responses not only block the functions of newly administered antibodies but also result in formation of immune complexes with the murine antibodies, which cause some side effects and could reduce the half life of the antibody. Second, the half-life of murine antibodies even in the absence of immune complex formation is much shorter than that of human antibodies *in vivo*. Third, the effector functions through the Fc region of murine antibodies are weak or non-existent compared to those of human antibodies. All of the factors described above reduce the efficacy of murine monoclonal antibodies and are common problems related to human immunotherapy based on xenogeneically derived monoclonal antibodies.

To overcome the intrinsic undesirable properties of murine monoclonal antibodies, recombinant murine antibodies engineered to incorporate regions of human antibodies, so called "humanized antibodies", have been developed. This alternative strategy was adopted as it was very difficult to generate human antibodies directed to human antigens, such as cell surface molecules, due to

- 4 -

tolerance of the immune system against self-antigens. A humanized antibody contains complementarity determining region (CDR) regions and a few other amino acid of a murine antibody and the rest of the structure is derived
5 from a human antibody.

Summary of the Invention

4-1BB is expressed on the surface of activated T-cells as a type of accessory molecule (Kwon et al., *Proc. Natl. Acad. Sci. USA* 86:1963 (1989); Pollok et al., *J. Immunol.* 151:771 (1993)), and is a membrane protein related to tumor necrosis factor receptor (TNFR) (Malett et al., *Immunol. Today* 12:220 (1991)). 4-1BB has a molecular weight of 55 kDa, and is found as a homodimer. In addition, 4-1BB binds to the protein kinase p56^{lck}
10 inside the cell. It has been suggested that 4-1BB mediates a signal transduction pathway from outside of the cell to inside (Kim et al., *J. Immunol.* 151:1255 (1993)).
15

A human 4-1BB gene was isolated from a cDNA library made from activated human peripheral T-cell mRNA (Goodwin et al., *Eur. J. Immunol.* 23:2631 (1993)). The amino acid sequence of human 4-1BB shows 60% homology to mouse 4-1BB (Kwon et al., *Proc. Natl. Acad. Sci. USA* 86:1963 (1989)), which indicates that the sequences are highly conserved. Analysis of the amino acid sequence of 4-1BB indicates
20 that it belongs to the nerve growth factor superfamily, along with CD40, CD27, TNFR-I, TNFR-II, Fas, and CD30 (Alderson et al., *Eur. J. Immunol.* 24:2219 (1994)). When a monoclonal antibody is bound to 4-1BB expressed on the surface of mouse T-cells, anti-CD3 T-cell activation is
25 increased many fold (Pollok et al., *J. Immunol.* 150:771 (1993)).
30

4-1BB binds to a high affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells (Pollok et al., *J. Immunol.* 150:771 (1993); Schwarz et al., *Blood* 85:1043 (1995)). The interaction of 4-1BB and its ligand provides a costimulatory signal leading to T cell activation and growth (Goodwin et al., *Eur. J. Immunol.* 23:2631 (1993); Alderson et al., *Eur. J. Immunol.* 24:2219 (1994); Hurtado et al., *J. Immunol.* 155:3360 (1995); Pollock et al., *Eur. J. Immunol.* 25:488 (1995); DeBenedette et al., *J. Exp. Med.* 181:985 (1995). These observations suggest an important role for 4-1BB in the regulation of T cell-mediated immune responses (Ignacio et al., *Nature Med.* 3:682 (1997)).

The inventors have previously constructed a hybridoma producing a mouse monoclonal antibody that is specific for human 4-1BB (h4-1BB) expressed on the surface of activated T-cells (Korean patent laid-open no. 96-37064). As a result of the search by the inventors for an immunosuppressant specific for activated T-lymphocytes and that also has no adverse side effect, the inventors have constructed a humanized monoclonal antibody from a mouse monoclonal antibody to 4-1BB that is expressed only in activated T-lymphocytes (Korean patent laid-open no. 96-37064). The humanized monoclonal antibody has high affinity for 4-1BB. Administering the humanized anti-4-1BB monoclonal antibody to non-human primates does not elicit an anti-antibody response. Rather, it elicits strong immunosuppressive activity.

One object of the present invention is to provide a humanized monoclonal antibody that specifically binds 4-1BB, especially human 4-1BB (h4-1BB) that has a high affinity for 4-1BB (h4-1BB). The humanized antibodies of the present invention have high affinity for human 4-1BB,

- 6 -

and bear sequence similarity to human antibodies. Because the 4-1BB receptor protein that is specifically bound by the antibodies of the invention appears to be involved in activation of the immune response, the product can be used effectively to treat autoimmune diseases or it can be used as an immunosuppressant to prevent graft rejection. Because the antibodies of the present invention closely resemble human antibodies, they can be administered to a human patient without any negative side-effect, such as a human anti-mouse antibody response.

Another object of the present invention is to provide a pharmaceutical composition comprising the humanized anti-h4-1BB monoclonal antibody. The pharmaceutical composition is useful for treating autoimmune diseases or acting as an immunosuppressant to prevent graft rejection. As rheumatoid arthritis is thought to be caused by inappropriate activity of 4-1BB receptor, the composition is especially useful for treating rheumatoid arthritis.

Another object of the invention is to provide a diagnostic composition for diagnosis of immune dysfunctions related to over- or underactivity of 4-1BB receptor protein.

Brief Description of the Drawings

Figure 1 - Amino acid sequence comparison of the variable region of heavy (VH) and light chain (VL) of the humanized anti-human 4-1BB antibodies, Hz4B4-1 and Hz4B4-2. These sequences are compared with the amino acid sequence of mouse monoclonal antibody 4B4-1-1, human antibody VH M17750, and human antibody VL X82934.

Figure 2 - Location of the primers used in PCR synthesis of the genes encoding VH and VL of humanized antibody Hz4B4-1, and the location of humanization.

- 7 -

Figure 3 - Construction of the expression plasmid pRc-Hz4B4-k-gs and its restriction enzyme map.

Figure 4 - Construction of the expression plasmid pCI-Hz4B4-H and its restriction enzyme map.

5 Figure 5 - Location of the primer used in PCR synthesis of the genes encoding VH and VL of humanized antibody Hz4B4-2, and the location of humanization.

Figures 6a - 6i - Change in the production level of OVA-specific IgG in baboons that have been immunized with ovalbumin and treated with humanized antibody Hz4B4-1.

10 Figures 7a - 7d - Figs. 7a and 7b show the proportion of cells reacting with 4B4 monoclonal antibody with CD4⁺ and CD8⁺ T-cells from the peripheral blood of normal people and rheumatoid arthritis patients. Figs. 7c and 7d show
15 the proportion of cells reacting with 4B4 monoclonal antibody with CD4⁺ and CD8⁺ T-cells from peripheral blood and synovial fluid of normal people and rheumatoid arthritis patients.

Detailed Description of the Present Invention

20 The present invention is embodied in two humanized monoclonal antibodies made from mouse monoclonal antibody 4B4-1-1 (Korean patent laid open no. 96-37064) that specifically binds human 4-1BB. The humanized monoclonal antibodies were used in human tests.

25 The first humanized antibody Hz4B4-1 was made by grafting the antigen binding region, complementarity determining region (CDR), in the variable region of the mouse monoclonal antibody 4B4-1-1. In order to increase the antigen binding affinity of the humanized antibody,
30 several amino acid residues were substituted in the framework region (FR) to resemble mouse antibody. The result is that the antibody has almost the same antigen

- 8 -

binding affinity as the original mouse monoclonal antibody. The humanized antibody Hz4B4-1 is comprised of a light chain variable region having the amino acid sequence of SEQ ID NO:1 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:2.

In order to make Hz4B4-1 more like a human antibody, additional amino acids in the mouse framework (FR) and complementarity determining regions (CDRs) (see, pp. 24-28 of Hood et al., "Immunology", second ed. c. 1984 by Benjamin/Cumming Publishing Co., Inc., Menlo Park, CA, esp. Figs. 2-6 and 2-10; and pp. 288-296 of Paul, "Fundamental Immunology", third ed. c. 1993 by Raven Press, Ltd., New York, NY., esp. Table 2) were substituted at several sites to resemble human antibody, and as a result the humanized antibody Hz4B4-2 was constructed. Hz4B4-2 has an antigen binding affinity that is 5 times greater than Hz4B4-1, and has 7 times higher antigen binding affinity than the original mouse monoclonal antibody. Humanized antibody Hz4B4-2 has a light chain variable region having an amino acid sequence shown in SEQ ID NO:3 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:4.

Bacteria harboring the expression plasmid comprising the gene encoding the light chain Hz4B4-1 humanized antibody of the present invention, pRc-Hz4B4-Mok-gs, and the gene encoding the heavy chain, pCI-Hz4B4-MoH, were deposited at the Korean Institute of Science and Technology, Department of Life Sciences Institute Gene Bank, under accession numbers KCTC 0537BP and KCTC 0536BP, respectively, on October 27, 1998.

The cell line MH200-3, producing the antibody Hz4B4-1 and SB500-23, producing Hz4B4-2 were deposited at the Korean Institute of Science and Technology, Department of

- 9 -

Life Sciences Institute Gene Bank, under the accession numbers KCTC 0540BP and KCTC 0541BP, respectively, on October 27, 1998.

5 The humanized antibody of the invention exhibits high affinity for human 4-1BB, as well as sequence similarity to human antibody. The humanized antibody can be used to treat autoimmune diseases and can be used as an effective immunosuppressant without encountering adverse side-effects.

10 For this purpose, the humanized antibody of the invention can be used as the active ingredient in a pharmaceutical composition to treat autoimmune diseases, and can also be used as an immunosuppressant. The pharmaceutical composition can be formulated as an oral or
15 non-oral dosage form, for immediate or extended release. The composition can comprise inactive ingredients ordinarily used in pharmaceutical preparation such as diluents, fillers, disintegrants, sweeteners, lubricants and flavors. The pharmaceutical composition is preferably
20 formulated for intravenous administration, either by bolus injection or sustained drip, or for release from an implanted capsule. A typical formulation for intravenous administration utilizes physiological saline as a diluent.

Fab or Fab' portions of the antibodies of the
25 invention can also be utilized as the therapeutic active ingredient. Preparation of these antibody fragments is considered known in the art.

Formulation of antibodies for therapeutic administration is considered known in the art.

30 The dose for a patient population depends upon the specific antibody used, body weight, age, gender, state of health, diet, administration time and formulation of the composition, route of administration, and the disease to

- 10 -

be treated. A typical dose is from 0.1 mg/kg/day to 100 mg/kg/day. More typically the dose is from 1 mg/kg/day to 50 mg/kg/day.

The composition of the present invention can also include printed matter that describes clinical indications for which the antibodies can be administered as a therapeutic agent, dosage amounts and schedules, and/or contraindications for administration of the antibodies of the invention to a patient.

The antibodies of the invention can also be used in a diagnostic assay. One preferred format for a diagnostic assay of the invention is quantitation of cells in a sample that express h4-1BB on their surface. Methods for counting cells bearing particular surface markers are well-known in the art. For example, fluorescence activated cell sorting can be used. Another format for a diagnostic assay of the invention is to quantitate the amount of h4-1BB protein in a sample. There are many formats for performing such an assay known in the art, for example antigen-immobilized or sandwich format enzyme-linked immunosorbent assays.

The invention is illustrated by the following Examples. The Examples are offered by way of illustration of the present invention, and not by way of limitation.

Example 1: Design of the humanized antibody Hz4B4-1

In order to construct a humanized antibody, the amino acid sequences of the light chain and heavy chain variable regions of the mouse monoclonal antibody 4B4-1-1 (Korean laid-open application no. 96-37064) were compared with human sequences in the GenBank database. The human heavy chain variable region sequence M17750 (Dersimonian, H. et al., *J. Immunol.*, 139, 2496 (1987)) having the greatest

- 11 -

sequence similarity to the mouse 4B4-1-1 antibody heavy chain, and human light chain variable region sequence X82934 (Esposito, G. et al., Arch. Virol., 142, 601 (1997)) that has the most similarity to the mouse 4B4-1-1 antibody light chain were selected. In order to humanize the mouse monoclonal antibody 4B4-1-1, the CDR from the mouse antibody was grafted on to a human antibody. Also, 10 critical residues in the FR region of humanized light chain and 11 critical residues in the FR region of the humanized heavy chain were substituted with corresponding amino acids from the mouse 4B4-1-1 antibody.

The humanized antibody Hz4B4k-1 light chain variable region designed as above and humanized heavy chain variable region Hz4B4h-1 have the sequences designated SEQ ID NO:1 and SEQ ID NO:2, respectively. These sequences are compared with a light chain variable region sequence (SEQ ID NO:38) and a heavy chain variable region sequence (SEQ ID NO:39) of the mouse monoclonal antibody 4B4-1-1. These sequences are further compared to a light chain variable region sequence X82934 (SEQ ID NO:40) and a heavy chain variable region sequence M17750 (SEQ ID NO:41) of a human antibody. The alignment is shown in Figure 1.

Example 2: Construction of the gene encoding humanized antibody Hz4B4-1 and the expression plasmid

Primers were made that encompassed the base sequences in the regions in which the replacements were desired. These primers were KXA (SEQ ID NO:5), KXB (SEQ ID NO:6), KXC (SEQ ID NO:7), KXD (SEQ ID NO:8), KXE (SEQ ID NO:9), KXF (SEQ ID NO:10), KXG (SEQ ID NO:11), KXH (SEQ ID NO:12), AMH (SEQ ID NO:13), BMH (SEQ ID NO:14), CMH (SEQ ID NO:15), DMH (SEQ ID NO:16), EMH (SEQ ID NO:17), FMH (SEQ ID NO:18), GMH (SEQ ID NO:19), HMH (SEQ ID NO:20).

- 12 -

Among the above-described primers, the primers KXA (SEQ ID NO:5) to KXH (SEQ ID NO:12) were used to construct the gene encoding a humanized kappa light chain variable region. Primers AMH (SEQ ID NO:13) to HMH (SEQ ID NO:20) were used to construct the gene encoding a humanized heavy chain variable region. Figure 2 shows by the location of the primers the regions of humanization in the humanized antibody Hz4B4-1, including the genes encoding the VL (SEQ ID NO:42), and the VH (SEQ ID NO:43). For comparison, Figure 2 also shows the gene sequences of the light chain variable region (SEQ ID NO:44) and heavy chain variable region (SEQ ID NO:45) of the mouse monoclonal antibody 4B4-1-1.

The above primers were used to perform a polymerase chain reaction (PCR) using DNA encoding the light and heavy chain variable regions of the mouse monoclonal antibody to 4-1BB (Korean laid open patent no. 96-37064). The products were joined by an ordinary recombinant PCR method to form complete VL and VH cDNAs.

The PCR products of the humanized VL was cut with Hind III, then blunt ended with Klenow enzyme, and then cut again with Bgl II. The PCR product encoding VL that was made from primer HKD (SEQ ID NO:22) and primer Ryu-93 (SEQ ID NO:48), using the human VL (HCK) containing plasmid pAcS2-CK (Jin et al., *Virus Research*, 38:269-277 (1995)) as a template was inserted into a pBluescript™ plasmid. The so-constructed pBS-Ck plasmid was cut with SpeI, and blunt ended with Klenow enzyme, and then cut with BglIII. Thus, the plasmid pBS-Vk-Ck that contains the humanized VL was constructed.

To insert the humanized VL into an expression vector, the EPO gene-containing HindIII-SalI fragment was removed from plasmid pCDNA-EPO-dE1-gs (Korean patent application

- 13 -

no. 97-76923), and replaced with the humanized VL cDNA containing the NotI-SalI fragment from the plasmid pBS-Vk-Ck. The resultant plasmid is called pRc-Hz4B4-k-gs. Details of the construction of the expression plasmid pRc-Hz4B4-k-gs, and its restriction enzyme map are shown in Fig. 3.

To construct the heavy chain, similarly made PCR products of VH were cut with NotI and NheI. Then, the PCR product cDNA encoding the VH made from the plasmid pAcS2-CH (Jin et al., *Virus Research*, 38:269-277 (1995)), containing a human antibody VH gene, using primer HHCD (SEQ ID NO:21) and primer Ryu-101 (SEQ ID NO:49), was inserted into a pBluescriptTM plasmid. The plasmid pBS-Cr1 resulted. PBS-Cr1 was digested with NotI and NheI, and the plasmid pBS-Vh-Cr1 was constructed. In order to insert the gene encoding the humanized heavy chain into an expression vector, pBS-Vh-Cr1 as digested with NotI, and blunt ended with Klenow, and then digested again with SalI, and then inserted into the XhoI-SalI site of the plasmid pCI-neo, which resulted in the plasmid pCI-Hz4B4-H. The details of the construction of the plasmid pCI-Hz4B4-H and its restriction enzyme map are shown in Fig. 4.

The base sequence of the gene encoding the humanized light and heavy chains from each plasmid was confirmed by DNA sequence analysis. The humanized light and heavy chain genes in the expression plasmids were linked to a human cytomegalovirus (HCMV) promoter.

Example 3: Expression of humanized antibody Hz4B4-1 and selection of cells

CHO-K1 cells (ATCC CCL61) cultured in GDMEM containing 10% dialyzed calf serum (FBS) in 5% CO₂ at 37° C, were inoculated into a 6 cm diameter dish so that 5 x

- 14 -

10⁵ cells were obtained. GDMEM contains DMEM (Gibco) and 4.5g/l glucose, 15 mg/l phenol red, 1 mM sodium pyruvate, 1.75 g/l sodium bicarbonate, 500 µM asparagine, 30 µM adenosine, 30 µM guanosine, 30 µM cytidine, 30 µM uridine, 10 µM thymidine, and non-essential amino acids (GIBCO). 2.5 µg of plasmid pRc-Hz4B4-k-gs and 2.5 µg of pCI-Hz4B4-H made in Example 2 were combined and diluted in 0.3 ml OPTI-MEM ITM (GIBCO). Also, in 0.3 ml of OPTI-MEM ITM, 15 µl of lipofectamineTM (GIBCO) was diluted, mixed, and allowed to stand for 15 min.

The prepared CHO-K1 cells were washed 3 times in OPTI-MEM ITM. Next, the plasmid-lipofectamineTM mixture prepared as above was spread evenly over the cells. The cells were cultured in 5% CO₂ at 37° C for 6 hr. Then, the culture medium was changed to 3 ml of GDMEM containing 10% dialyzed calf serum, and the cells were cultured for an additional 48 hrs. In the culture medium, 3 ml of 0.25% trypsin (GIBCO) was added at 37° C and allowed to react for 3 minutes, and centrifuged (1,000xg, 5 min.). The cells thus obtained were placed into 96-well plates at 2 x 10³ cells per well. After 48 hr, 5 µM methionine sulfoxamine (MSX) was added to the GDMEM containing 10% dialyzed calf serum and the cells were cultured in 5% CO₂ at 37° C. The culture medium was changed every 4 days; the culture was continued for 2 weeks.

The ability of each surviving cell clone to produce antibodies was assayed. An ELISA sandwich assay using goat anti-human IgG (Sigma) conjugated to horseradish peroxidase (HRP) (Park et al., *Hybridoma*, 15, 435-441 (1996)) was carried out to obtain clones producing antibodies. Among these, 5 clones (A6B, A9A, B1F, 212A, A7B) exhibited high production of antibodies. These 5

- 15 -

clones were placed in GDMEM containing 10% dialyzed calf serum. 100, 200, 350, 500 and 1000 μ M MSX was added to each culture, and the cell clones that were most viable and that produced the most highest amount of antibodies were determined and separated out. The 3 clones that produced the largest amount of the product are shown in Table 1.

Table 1

Clone	Conc. of MSX (μ M)	Production of Ab (μ g/ 10^6 cells/day)
A6B-200-2	200	11.3
MH200-2	200	12.2
MH200-3	200	16.2

10 **Example 4: Isolation and purification of humanized antibody Hz4B4-1**

The cells of the clone MH200-3 obtained in Example 3 were cultured in T175 flasks containing serum-free media (CHO-S-SFMII, GIBCO) in 5% CO₂ at 37° C. The culture conditioned medium was applied to a Protein G-Sepharose column (Pharmacia). The antibodies that bound to the column were eluted with 0.1 M glycine (pH 2.7), neutralized with 1M Tris (pH 9.0), and dialyzed with PBS buffer (pH 7.0). The purified antibodies were electrophoresed on 10% SDS-PAGE. Bands of about 55 kDa (heavy chain) and about 25 kDa (light chain) were observed indicating that the humanized antibodies were purified.

Example 5: Antigen-binding affinity of humanized antibody Hz4B4-1

The binding affinity of the mouse monoclonal antibody 4B4-1-1 and humanized antibody were determined and compared using the BIAcore™ assay (Pharmacia). Rabbit anti-mouse IgG (Sigma) and goat anti-human IgG (Fc-specific) were each diluted in 10 mM acetic acid buffer, and coupled to a Dextran CM-5 sensor chip (Pharmacia). 1 M ethanolamine was added to stop the reaction. Mouse monoclonal antibody 4B4-1-1 and humanized antibody Hz4B4-1 were each diluted to a concentration of 50 µg/ml in HEPES buffer (HBS). The coupled antibodies were bound at 100 resonance units (R.U.), and 25 µg/ml of 4-lBB antigen was applied at a flow rate of 10 µl/min. and bound for 5 minutes. HBS buffer (Pharmacia) was applied for 5 minutes at the same flow rate so that dissociation would occur. The association rate and dissociation rates and corresponding rate constants were determined by using BIA evaluation software. The results are shown in Table 2 as k_{on} and k_{off} values; K_d is also shown.

Table 2

Antigen binding affinity of humanized antibody Hz4B4-1

Antibody	k_{on} ($M^{-1}s^{-1}$)	k_{off} (s^{-1})	K_d (M)
Mouse monoclonal antibody 4B4-1-1	1.16×10^4	1.54×10^{-6}	1.33×10^{-10}
humanized antibody Hz4B4-1	5.00×10^4	4.36×10^{-6}	8.72×10^{-11}

- 17 -

The results above show that the humanized antibody Hz4B4-1 has greater association and dissociation rate with the antigen compared with the mouse antibody. The antigen binding affinity (K_d) was about 1.5 times greater than the mouse antibody.

Example 6: Design of the humanized antibody Hz4B4-2

In order to humanize HzHB4-1 even more, one amino acid residue in CDR1 of the light chain, and 8 amino acid residues in the mouse FR were replaced with corresponding human amino acid residues. Also, 4 amino acid residues were replaced in CDR2 of the humanized heavy chain, and 8 amino acid residues were replaced in the mouse FR with corresponding residues from a human antibody. As indicated above, the novel humanized light chain Hz4B4k-2 and humanized heavy chain Hz4B4h-2 have the amino acid sequence of SEQ ID NOS:3 and 4, respectively. These sequences were aligned with mouse monoclonal antibody 4B4-1-1 VL (SEQ ID NO:38) and VH (SEQ ID NO:39), human antibody VL X82934 (SEQ ID NO:40) and VH M17750 (SEQ ID NO:41), and Hz4B4-1 humanized antibody sequences (SEQ ID NOS:1 and 2), The alignment is shown in Fig. 1.

Example 7: Construction of the gene encoding humanized antibody Hz4B4-2 and the expression plasmid

Primers were synthesized that encompassed the base sequences in the regions in which the substitutions were desired. These primers were MOKA (SEQ ID NO:23), MOKB (SEQ ID NO:24), MOKC (SEQ ID NO:25), MOKD (SEQ ID NO:26), MOKE (SEQ ID NO:27), MOKF (SEQ ID NO:28), MOKG (SEQ ID NO:29), MOKH (SEQ ID NO:30), MOHA (SEQ ID NO:31), MOHB (SEQ ID NO:32), MOHC (SEQ ID NO:33), MOHD (SEQ ID NO:34), MOHE (SEQ ID NO:35), MOHF (SEQ ID NO:36), MOHG (SEQ ID NO:37).

Among the above primers, MOKA (SEQ ID NO:23) to MOKH (SEQ ID NO:30) were used to construct the gene encoding humanized kappa light chain variable region. Primers MOHA (SEQ ID NO:31) to MOHG (SEQ ID NO:37) were used to
5 construct the gene encoding the humanized heavy chain variable region. In addition, primer HMH (SEQ ID NO:20) was also used in the construction of the gene encoding humanized heavy chain variable region. Fig. 5 shows the humanized region of Hz4B4-1, and the VL gene (SEQ ID
10 NO:42) and VH gene (SEQ ID NO:43) of Hz4B4-1.

The above MOK* series of primers were used with the light chain gene of the Hz4B4-1 antibody as a template to produce a gene encoding the light chain of the humanized antibody for Hz4B4k-2. The above MOH* series of primers
15 was used with the heavy chain gene of Hz4B4-1 as a template to produce a VH gene and an ordinary recombinant PCR method was carried out to further humanize the antibody. The genes encoding VL (Hz4B4k-2, SEQ ID NO:46) and VH (Hz4B4h-2, SEQ ID NO:47) were synthesized. The
20 Hz4B4k-2 DNA obtained above was cut with XbaI and BglII and inserted into the XbaI/BglII site of the Hz4B4-1 light chain expression vector, pRC-Hz4B4-k-gs. Thus, the Hz4B4-2 light chain expression plasmid pRC-Hz4B4MoK-gs was constructed.

25 In the case of the heavy chain, the Hz4B4h-2 DNA was cut with XhoI and NheI, and inserted into the XhoI/NheI site of the heavy chain expression vector pCI-Hz4B4-H. Thus, the humanized antibody Hz4B4-2 heavy chain expression plasmid pCI-Hz4B4-MoH was constructed.

30 The base sequence of the gene encoding the humanized light and heavy chains from each plasmid was confirmed by DNA sequence analysis.

Example 8: Expression of humanized antibody Hz4B4-2 and selection of cells

As in Example 3 above, CHO-K1 cells were transfected with pRC-Hz4B4-Mok-gs and pCI-Hz4B4-MoH, and the transformed cells were incubated for 2 weeks in GDMEM culture medium that contains 25µM methionine sulfoximine (MSX), at 37 °C, in 5% CO₂. Resistant clones were isolated, and antibody production was determined by sandwich ELISA. Among these clones, the high producing SB clones were cultured in GDMEM medium that contains 10% dialyzed calf serum, to which 100, 200, 350, 500 or 1000 µM MSX was added. The clones that were most viable and high antibody producers at 500 µM MSX were separated out. These clones produced about 3 µg/10⁶ cells/day of antibody.

Example 9: Isolation and purification of humanized antibody Hz4B4-2

As in Example 4, the above SB500 cells were cultured in serum-free medium. The conditioned culture medium was applied to a protein G-Sepharose (Pharmacia) affinity column. The purified antibodies were electrophoresed on 10% SDS-PAGE. Bands of about 55 kDa (heavy chain) and about 25 kDa (light chain) were observed, indicating that the humanized antibodies had been purified.

Example 10: Antigen-binding affinity of humanized antibody Hz4B4-2

The antigen binding affinity of the purified Hz4B4-2 humanized antibody was measured as in Example 5 using the BIAcore™ assay (Pharmacia). The results are shown in Table 3.

- 20 -

Table 3

Antigen binding affinity of humanized antibody Hz4B4-2

Antibody	k_{on} ($M^{-1}s^{-1}$)	k_{off} (s^{-1})	K_d (M)
Mouse monoclonal antibody 4B4-1-1	1.16×10^4	1.54×10^{16}	1.33×10^{-10}
Humanized antibody Hz4B4-1	5.00×10^4	4.36×10^{-6}	8.72×10^{-11}
Humanized antibody Hz4B4-2	1.17×10^4	2.14×10^{-6}	1.83×10^{-11}

As shown in Table 3, Hz4B4-1 has 1.5 times greater antigen binding affinity (K_d) compared to mouse monoclonal antibody 4B4-1-1. Humanized antibody Hz4B4-2 has 7.3 times greater antigen binding affinity compared the mouse monoclonal antibody. It is expected that the humanized antibodies Hz4B4-1 and Hz4B4-2 of the invention will have the same affinity in human beings.

10

Example 11: Experimental Results - Immune response to and immunosuppressive effect of the humanized antibody

A. Immune response in baboon and administration of the humanized antibody Hz4B4-1

15

Seven- to eight-year-old male and female baboons (*P. anubis*), weighing 12 to 15 kg, at the Southwest Foundation for Biomedical Research (San Antonio, Texas), were used. The baboons were divided into three groups of two males and one female per group,

- 21 -

and maintained under standard animal housing conditions. Each animal was immunized intramuscularly with 1 mg of OVA (Sigma) emulsified in aluminum hydroxide (Sigma). The time of OVA-immunization was designated as week 0, and OVA (1mg in PBS) was given again at week 6. The first injection of humanized antibody (or PBS, control group) was given at the time of the first OVA-immunization (week 0), and subsequent injections of humanized antibody or PBS were given at weeks 1, 2, 3, 6, 7, 8, and 9. The first group of three baboons (control group) was injected intravenously with 10ml PBS. The second and third groups were treated with the humanized antibody Hz4B4-1 obtained in Example 4, at 1 or 4 mg/kg of body weight, respectively. Blood samples were collected at week -1.5, week 0, and at weekly intervals until week 10.

B. Evaluation of host humoral immune response

Anti-OVA and IgM levels were determined by ELISA. Immunomaxisorp™ plates (Nunc InterMed, Rockilde, Denmark) were coated with OVA at a concentration of 500 ng/well. After blocking with 1% bovine serum albumin, serial twofold dilutions of serum samples obtained in step 1 above, starting at 1/32 dilution, were added to the wells at 0.1 ml per well. The plates were incubated for 4 hours at room temperature. Bound IgG and IgM were detected with alkaline phosphatase (AP)-conjugated rabbit anti-monkey IgG (Sigma) or AP-conjugated goat anti-human IgM (Sigma), respectively by adding 0.1 ml of the conjugates to each well and incubating at the above temperature. A₄₀₅ was read by an automatic microplate reader

(Molecular Devices Corp., Menlo Park, California). IgG or IgM titer was determined at the highest dilution, which gave the absorbance three or five times the background reading at A_{405} , respectively.

5 Total IgG or Hz4B4-1 in the sera was quantified by ELISA. Diluted serum samples were added as above to the plates coated with goat anti-human IgG (150 ng/well) or GST-4-1BB (100 ng/well) and incubated for 4 hours at the above indicated temperature. After
10 incubation, AP-conjugated goat anti-human IgG (Sigma) was added to each well of the plates and development of the reaction was performed using *p*-nitrophenyl phosphate, using an automatic microplate reader at A_{405} . The results are shown in Table 4 and Figs. 6a to
15 6i. The concentrations of total IgG or Hz4B4-1 in each sample was calculated with reference to standard curves generated by using human IgG or purified Hz4B4-1, respectively.

20

25

30

Table 4

Exp. Animal No.	Dose of Hz4B4-1 (mg/kg)	Ratio of OVA-specific IgG titer at wk 7 to OVA-specific IgG titer at wk 0	Ratio of OVA-specific IgM titer at wk 7 to OVA-specific IgM titer at wk 0	Ratio of serum conc. of total IgG at wk 7 to serum conc. of total IgG at wk 1	Serum conc. of Hz4B4-1 at wk 1 (µg/ml)
A1	0	64	2	1.13	-
A2	0	16	1	1.02	-
A3	0	32	1	1.05	-
B1	1	2	1	0.96	6.66
B2	1	128	1	1.06	0.42
B3	1	2	1	1.01	3.85
C1	4	4	2	1.09	25.74
C2	4	1	0.5	1.16	10.14
C3	4	2	1	1.09	14.49

A distinguishable increase of the anti-OVA IgG level in the serum was found in the control group. The highest titers were observed at week 7, a week after the second immunization with OVA, and were 64-, 16-, and 32-fold greater than the titer at week 0 in baboons A1, A2, and A3, respectively (Table 4 and Figs. 6a, 6b, and 6c). In contrast, significant suppression of the OVA-specific Ab response was found in Hz4B4-1-treated baboons. In the second group, which was treated with a dose of 1 mg/kg of Hz4B4-1, two of three baboons (B1 and B3) showed the suppression. The titers at week 7 were twofold higher than those at week 0 (Table 1, and Figs. 6d, 6e, and 6f). However, the suppression was not detected in baboon B2, which showed a 128-fold increase in titer between week 7 and week 0. In the case of the third group, which was treated with 4 mg/kg of Hz4B4-1, the suppression was shown

- 24 -

in all three baboons. The titer increase was four-, one-, and two-fold for baboons C1, C2, and C3, respectively (Table 1, and Figs. 6g, 6h, and 6i).

No distinguishable increase in anti-OVA IgM titer was observed in any of the animals, irrespective of whether they were treated with Hz4B4-1, indicating that Hz4B4-1 treatment did not affect the IgM production at a detectable level. Taken together, the data suggest that a state of humoral unresponsiveness to OVA, a T cell-dependent antigen, was induced by Hz4B4-1 treatment. This was further indicated by measuring the serum concentration of Hz4B4-1. The serum concentration of Hz4B4-1 was highest at week 1 in all baboons. The concentration of Hz4B4-1 in the serum of baboon B2, which did not show OVA-specific IgG suppression, was significantly lower compared with those of baboons B1 and B3 treated with the same dose of Hz4B4-1 (Table 1).

The amount of total IgG at week 0 was compared with that of week 7 in each baboon. As shown in Table 1, the total IgG amount was little altered, regardless of the treatment with Hz4B4-1. In addition, during the treatment with Hz4B4-1, no significant variations were observed in total numbers and proportions of B and T cells in each blood sample analyzed by flow cytometry. Collectively, the data indicated that the immune unresponsiveness by treatment with Hz4B4-1 was Ag-specific, and not due to overall immune suppression.

C. Analysis of 4-1BB-positive T-cells

To evaluate the clinical significance of 4-1BB molecules, the expression of these molecules on T lymphocytes of patients with rheumatoid arthritis (RA) was analyzed by FACS analysis using 4B4 MAb. PBMC was prepared

- 25 -

from heparinized venous blood withdrawn from normal volunteers or RA patients, and synovial cells were obtained from synovial fluid aspirated from RA patients. 5×10^5 PBMC or synovial cells were incubated with 5 μ l of phycoerythrin (PE)-labeled anti-human CD4 or PE-labeled anti-human CD8 mouse MAb (Immune Source, Los Altos, California) in a staining buffer that contains DMEM (1% BSA and 0.005% NaNH₃) for 30 min at 4°C in the dark. After incubation, cells were washed with staining buffer, and then incubated with 5 μ l of FITC-labeled 4B4 MAb for 30 min at 4°C in staining buffer. The percentage of 4-1BB expressing T lymphocytes was analyzed by flow cytometry. The expression of 4-1BB molecules on T lymphocytes was analyzed on a FACStar Plus™ cytometer (Becton Dickinson & Co., Mountain View, California).

The expression of these molecules on peripheral blood (PBMC) T lymphocytes of 41 RA patients was compared with those of 13 normal individuals. The results are shown in Figs. 7a and 7b. The reactivity with 4B4 MAb of CD4 or CD8 T lymphocytes of normal individuals was very low or not observed: CD4+, <0.5%; CD8+, <1,2%. In contrast, the CD4+ or CD8+ T lymphocytes from some of the RA patients showed the increased reactivity to 4B4 MAb. In the case of CD4+ T cells, the reaction rates were above 1% in 18 of 41 patients and peaked at 7.5%. In CD8+ T cells, 17 of 38 patients showed reaction rates above 2%, with a maximum value of 15%.

RA is characterized by chronic synovitis. Affected synovial tissues are infiltrated with lymphocytes and plasma cells. This disease is initiated by activation of T lymphocytes responding to some arthritogenic agents, and T lymphocytes play a primary role in the pathogenesis of RA, indicating that T lymphocytes in synovial fluid of RA

patients are in an activated state (G.S. Firestein, p. 851 in "Etiology and Pathogenesis of Rheumatoid Arthritis", 5th ed., W.N. Kelley et al. eds., c. 1997 by W.B. Saunders, Philadelphia, PA). Therefore, the expression of 4-1BB molecules in synovial fluid T lymphocytes of 13 RA patients were compared with those in the peripheral blood T lymphocytes of the same patients. The results are shown in Figs. 7c and 7d. CD4+ and CD8+ T lymphocytes in synovial fluid showed more reactivity to 4B4 MAb than those in peripheral blood; for the CD4+ or CD8+ subset, above twofold in 8 or 9 RA patients out of 13. Each line between two circles means that the corresponding PBMC and SFC were obtained from the same patient. These findings suggest that the expression of 4-1BB may be related to the disease process of RA.

Without being bound by any theory of the invention, the inventors speculate that there are two not mutually exclusive mechanisms of the immunosuppressive effect of the H4B4-1. First, the antibody could interfere with 4-1BB/4-1BBL interaction that plays an important role in T cell activation. Second, the antibody could eliminate 4-1BB expressing T cells via complement-dependent cytotoxicity and antibody-dependent cellular toxicity. In many cases of T cell mediated autoimmune diseases, autoantigens are not well defined or are too diverse to manipulate the immune response against the autoantigens. In this regard, functional blocking and/or elimination of activated T cells, most of which are probably autoantigen specific in patients with autoimmune diseases, could be approaches to ameliorate the disease. The inventors have discovered that a substantial proportion of T cells in PBMC and synovial fluid from RA patients express 4-1BB, which suggests that 4-1BB could be an ideal target for

- 27 -

antibody mediated therapy for RA since only activated T cells, possibly most pathologic T cells, express 4-1BB. In this regard, a longer expression time of 4-1BB (more than 72 hours) than those of other costimulatory molecules such as CD40L, may be another advantageous point for targeting 4-1BB with the antibody. Beyond RA, Hz4B4-1 could also be used for the treatment of other T cell mediated autoimmune diseases and graft rejections.

10 The present specification includes the appended Sequence Listing of 49 nucleic acid or amino acid sequences. Articles of the patent and scientific periodical literature cited herein are hereby incorporated in their entirety by such citation.


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1


TO: Hong Hyo-Jeong
KIT Apt. 15-401, #236-2 Gajeong-dong, Yuseong-ku, Taejeon 305-350,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> DH5^α /PCI-HZ4B4-MOH	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0536BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The Microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on October 27 1998	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yuseong-ku, Taejeon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  PARK Yong-Ha, Director Date: November 04 1998

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1

TO: Hong Hyo-Jeong
KIT Apt. 15-401, #236-2 Gajeong-dong, Yusong-ku, Taejon 305-350,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: MH200-3	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0540BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The Microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on October 27 1998	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  PARK Yong-Ha, Director Date: November 08 1998


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Hong Hyo-Jeong
KIT Apt. 15-401, #236-2 Gajeong-dong, Yusong-ku, Taejon 305-350,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: BB500-23	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0541BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The Microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on October 27 1998	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  PARK Yong-Ha, Director Date: November 06 1998

We claim:

1. A composition comprising at least one humanized antibody, wherein said at least one humanized antibody comprises:
 - a) an antibody light chain comprising a light chain
5 of a human monoclonal antibody having the complementarity determining regions of the antigen binding domain substituted by the complementarity determining regions of the antigen binding domain of the light chain of a mouse monoclonal antibody that specifically binds to h4-1BB
10 protein; and
 - b) an antibody heavy chain comprising a heavy chain
of a human monoclonal antibody having the complementarity determining regions of the antigen binding domain substituted by the complementarity determining regions of
15 the antigen binding domain of the heavy chain of a mouse monoclonal antibody that specifically binds to h4-1BB protein.
2. The composition of claim 1, wherein the entire
20 antigen binding domain of said light chain of a human monoclonal antibody is substituted by the entire antigen binding domain of said light chain of a mouse monoclonal antibody.
3. The composition of claim 1, wherein a part of
25 the antigen binding domain joining said complementarity determining regions of said light chain of a human monoclonal antibody is substituted by the corresponding part of the antigen binding domain of said light chain of a mouse monoclonal antibody.

4. The composition of claim 1, wherein the entire antigen binding domain of said heavy chain of a human monoclonal antibody is substituted by the entire antigen binding domain of said heavy chain of a mouse monoclonal antibody.

5. The composition of claim 1, wherein a part of the antigen binding domain joining said complementarity determining regions of said heavy chain of a human monoclonal antibody is substituted by the corresponding part of the antigen binding domain of said heavy chain of a mouse monoclonal antibody.

6. The composition of claim 2, wherein the entire antigen binding domain of said heavy chain of a human monoclonal antibody is substituted by the entire antigen binding domain of said heavy chain of a mouse monoclonal antibody.

7. The composition of claim 1, wherein up to ten amino acids in the framework portion of the light chain are substituted by corresponding amino acids from a mouse monoclonal antibody that specifically binds to h4-1BB protein.

8. The composition of claim 1, wherein up to 11 amino acids in the framework portion of the heavy chain are substituted by corresponding amino acids from a mouse monoclonal antibody that specifically binds to h4-1BB protein.

9. The composition of claim 7, wherein up to 11 amino acids in the framework portion of the heavy chain

are substituted by corresponding amino acids from a mouse monoclonal antibody that specifically binds to h4-1BB protein.

10. The composition of claim 1 wherein the K_d of said
5 at least one humanized antibody for h4-1BB is less than or equal to 8.7×10^{-11} M.

11. The composition of claim 1 that comprises at least two of said humanized antibodies.

12. The composition of claim 1, wherein said at
10 least one humanized antibody is produced by the cell line deposited as KCTC 0540BP or as KCTC 0541BP.

13. The composition of claim 11, wherein said at least two humanized antibodies are produced by the cell lines deposited as KCTC 0540BP and KCTC 0541BP.

15 14. A humanized antibody comprising:

- a) a light chain variable region comprising a polypeptide having the amino acid sequence of SEQ ID NO:1;
- b) a heavy chain variable region comprising a polypeptide having the amino acid sequence of SEQ ID NO:2;
- 20 c) a light chain constant region identical to a human antibody light chain constant region; and
- d) a heavy chain constant region identical to a human antibody constant region.

15. The humanized antibody of claim 14, wherein said
25 humanized antibody is expressed from cells of the cell line deposited as KCTC 0540BP.

16. A humanized antibody comprising:

- a) a light chain variable region comprising a polypeptide having the amino acid sequence of SEQ ID NO:3;
- b) a heavy chain variable region comprising a polypeptide having the amino acid sequence of SEQ ID NO:4;
- c) a light chain constant region identical to a human antibody light chain constant region; and
- d) a heavy chain constant region identical to a human antibody constant region.

10

17. The humanized antibody of claim 14 or 16 wherein the heavy chain is a gamma 1, gamma 2, gamma 3 or gamma 4 chain.

18. The humanized antibody of claim 14 or 16 wherein the light chain is a kappa or lambda light chain.

19. The humanized antibody of claim 16, wherein said humanized antibody is expressed from cells of the cell line deposited as KCTC 0541BP.

20. A plasmid comprising a polynucleotide encoding a light chain variable region of a humanized antibody, wherein said plasmid is pRC-Hz4B4-k-gs or pRC-Hz4B4-Mok-gs resident in cells deposited as KCTC 0537BP .

21. A plasmid comprising a polynucleotide encoding a heavy chain variable region of a humanized antibody, wherein said plasmid is pCI-Hz4B4-H or pCI-Hz4B4-MoH resident in cells deposited as KCTC 0536 BP.

22. A host cell transformed with the plasmid of claim 20.

23. A host cell transformed with the plasmid of claim 21.

24. A cell of a cell line deposited as KCTC 0540BP or as KCTC 0541BP.

5 25. A method for suppressing an immune response in a subject comprising administering to said subject an amount of the composition of any one of claims 1 and 10-13, or with a composition comprising an antibody of any one of claims 14-19, effective for inhibiting T cell activation.

10 26. A method for screening a patient for an autoimmune response comprising contacting a sample from said patient with an antibody that specifically binds to H4-1BB protein, and determining the number of CD4⁺ and CD8⁺ cells that are specifically bound by said antibody,
15 wherein finding greater than 1% of said CD4⁺ cells or greater than 2% of said CD8⁺ cells are labeled indicates an autoimmune response.

27. The method of claim 25, wherein said antibody is an antibody of any one of claims 12-15.

20 28. A composition for immunosuppression comprising (i) the composition of any one of claims 1 and 10-13 or (ii) comprising an antibody of any one of claims 14-19, and a pharmaceutically acceptable carrier.

25 29. The composition of claim 28, further comprising printed matter describing the administration of said

composition to a patient exhibiting symptoms of an autoimmune disease.

30. The composition of claim 29, wherein said autoimmune disease is rheumatoid arthritis.

5 31. A method for suppressing an immune response in a patient comprising administering the composition of claim 28 to said patient in an amount effective to suppress said immune response.

10 32. The method of claim 31, wherein said immune response is transplant rejection.

1/18
FIG. 1

KAPPA LIGHT CHAIN

4B4-1-1 DIVMTQSQATQSVTPGDRVSLSC RASQTISDYLH WYQQKSHESPRLLIK
 X82934 DVVMTQSPATLSVSPGERATLSC RASQSVSSYLA WYQQKPGQAPRLLIY
 Hz4B4-1 DIVMTQSPATQSVSPGERVTLSC RASQTISDYLH WYQQKPGQSPRLLIK
 Hz4B4-2 -----P-L-L-----S-----

4B4-1-1 YASQSIG GIPSRFSGSGSGDFTLSINSVEPEDVGVYYC QDGHSPPT FGGGTKLEIK
 X82934 DASRRAT GIPARFSGSGSGDFTLTSSLEPEDFAVYYC QRSNWPLT FGGGTKVEIK
 Hz4B4-1 YASQSIG GIPSRFSGSGSGDFTLTSSVEPEDFGVYYC QDGHSPPT FGGGTKLEIK
 Hz4B4-2 -----A-----T-----L-----A-----V---


HEAVY CHAIN

4B4-1-1 QVQLQQGAELVKPGASVKLSCKASGYTFS SYWMH WVKQRPQVLEWIG EINPQNGHTNYNEKFKS
 M17750 QVQLVQSGAEVKKPGASVKVSKASGYTFT SYAMH WVRQAPGQRLEWMG WINAGNGNTKYSQKFQG
 Hz4B4-1 QVQLVQSGAEVVKPGASVKLSCKASGYTFS SYWMH WVKQAPQVLEWIG EINPQNGHTNYNEKFKS
 Hz4B4-2 -----K-----V-----R-----R---M-----SQ--QG

4B4-1-1 KATLTVDKSSSTAYMQLSSLTSEDAVYYCAR SFTTARAFAY WGQGLVTVSA
 M17750 RVTITRDTSASTAYMELSSLRSEDAVYYCAR GGYGSGSNY WGEGLVTVSS
 Hz4B4-1 KATLTVDKSASTAYMELSSLRSEDAVYYCAR SFTTARAFAY WGQGLVTVSS
 Hz4B4-2 RV-I-----

2/18

FIG. 2



3/18

FIG. 2 (Continued)

VH of humanized antibody Hz4B4-1

4B4-1-1 GCGGCCACCATGGGATGGAGCTATATCATCTCTTTTGGTAGCAACAGCTACAGATGTCCACTCC

MET

Hz4B4-1 GCGGCCACCATGGGATGGAGCTATATCATCTCTTTTGGTAGCAACAGCTACAGATGTCCACTCC

→ AMH

← BMH

CAGGTCCAACTGCAGCAGCCTGGGGCTGAACCTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCTCTGCAAGGCTTCTGGCTACACCTTCAGC
 Q V Q L Q Q P G A E L V K P G A S V K L S C K A S G Y T F S
 Q V Q L V Q S G A E V V K P G A S V K L S C K A S G Y T F S
 CAGGTCCAACTGGTGCAGTCTGGGGCTGAAGTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCTCTGCAAGGCTTCTGGCTACACCTTCAGC

→ CMH

AGCTACTGGATGCACCTGGGTGAAGCAGAGGCCCTGGACAAGTCTTGAGTGGATTGGAGAGATTAACTCTGGCAACGGTCATACTAACTAC
 S Y W M H W V K Q R P G Q V L E W I G E I N P G N G H T N Y
 S Y W M H W V K Q A P G Q V L E W I G E I N P G N G H T N Y
 AGCTACTGGATGCACCTGGGTGAAGCAGGCCCTGGACAAGTCTTGAGTGGATTGGAGAGATTAACTCTGGCAACGGTCATACTAACTAC

→ EMH

← DMH

AATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCTCCAGGCACAGCCTACATGCAACTCAGCAGCCTGACATCTGAGGAC
 N E K F K S K A T L T V D K S S T A Y M Q L S S L T S E D
 N E K F K S K A T L T V D K S S T A Y M E L S S L R S E D
 AATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCCGGAGGCACAGCCTACATGGAGCTCAGCAGCCTGAGATCTGAGGAC


← FMH


TCTGCGGTCATTACTGTGCAAGATCTTTTACTACGGCAGGGGGTGTGCTTACTGGGGCCAAAGGACTCTGGTCACTGTCTCTGCA
 S A V Y Y C A R S F T T A R A F A Y W G Q G T L V T V S A
 T A V Y Y C A R S F T T A R A F A Y W G Q G T L V T V S S
 ACGGCGGTCATTACTGTGCAAGATCTTTTACTACGGCAGGGGGTGTGCTTACTGGGGCCAAAGGACTCTGGTCACTGTCTCTTCA

→ GMH

← HMH

4/18
FIG. 3



5/18
FIG. 4

6/18

FIG. 5

VL of humanized antibody Hz4B4-2

Hz4B4-1/Hz4B4-2 ACTAGAGCTTCATCAGACAGGAGGGAAGCAAGATGGAATTCACAGGCCAGGTTCTTATGTACTGCTG
MOKA → MET

TATGGGTATCTGGTACCTGTGGG

Hz4B4-1 GACATTGTGATGACCCAGTCTCCAGCCACCCAGTCTGTCTCCAGGAGAAAGATCACCCCTTCTCTGCAGGGCCAGCCAGACTATTAGC
D I V M T Q S P A T Q S V S P G E R V T L S C R A S Q T I S
D I V M T Q S P P T L S L S P G E R V T L S C R A S Q S I S
Hz4B4-2 GACATTGTGATGACCCAGTCTCCACCAACCTTCTCTGTCTCCAGGAGAAAGATCACCCCTTCTCTGCAGGGCCAGCCAGTCCATTAGC
MOKB ← MOKC → MOKD

GACTACTTACACTGGTATCAACAAAACCTGGCCAGTCTCCAAGGCTTCTCATCAAAATATGCTTCCCAATCCATCTCTGGGATCCCCCTCC
D Y L H W Y Q Q K P G Q S P R L L I K Y A S Q S I S G I P S
D Y L H W Y Q Q K P G Q S P R L L I K Y A S Q S I S G I P A
GACTACTTACACTGGTATCAACAAAACCTGGCCAGTCTCCAAGGCTTCTCATCAAAATATGCTTCCCAATCCATCTCTGGGATCCCCGGCT
MOKE → MOKF

AGGTTTCAGTGGCAGTGGATCAGGGTCAGATTTCACCTCACCATCAGCAGTGTGGAACCTGAAGATTTTGGAGTGTATTACTGTCAAGAT
R F S G S G S G S D F T L T I S S V E P E D F G V Y Y C Q D
R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q D
AGGTTTCAGTGGCAGTGGATCAGGGACCGATTTCACCTCACCATCAGCAGTCTGGAACCTGAAGATTTTGGTGTATTACTGTCAAGAT
MOKG

GGTCACAGCTTTCTCCGACGTTCCGGTGGAGGCCACCAAGCTAGAAATCAA
G H S F P P T F G G G T K L E I K
G H S F P P T F G G G T K V E I K
GGTCACAGCTTTCTCCGACGTTCCGGTGGAGGCCACCAAGTGGAAATCAA
MOKH ←

FIG. 5 (Continued)

VH of humanized antibody H24B4-2

HZ4B4-1
 GCCGCCACCATGGGATGGAGCTATATCATCTCTTTTGGTAGCAACAGCTACAGATGTCCACTCCCAGGTCCCAA
 MET Q V Q

HZ4B4-2
 MET
 GCCGCCACCATGGGATGGAGCTATATCATCCTCTTTTGGTAGCAACAGCTACAGATGTCCACTCCAGGTCCAA
 MOHA → Q V Q

CTGGTGCAGCTCTGGGGCTGAAGTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCTCTGCAAGCTTCTGGCTACACCTTCAGCAGCTACTGG

L V Q S G A E V V K P G A S V K L S C K A S G Y T F S S Y W

L V Q S G A E V K K P G A S V K V S C K A S G Y T F S S Y W

CTGGTGCAGTCTGGGGCTGAAGTGAAGAGCCTGGGGCTTCAGTGAAGGTGTCTCTGCAAGCTTCTGGCTACACCTTCAGCAGCTACTGG

MOHB ← → MOHC

ATGCACTGGGTGAAGCAGGCCCTGGACAAGTCCCTTGAGTGGATTGGAGAGATTAACTCTGGCAACGGTCATATACTAACTACAATGAGAAG

M H W V K Q A P G Q V L E W I G E I N P G N G H T N Y N E K

M H W V R Q A P G Q R L E W M G E I N P G N G H T N Y S Q K

ATGCACTGGGTGCGCAGGCCCTGGACAA CGCCTTGAGTGGATTGGAGAGATTAACTCTGGCAACGGTCATATACTAACTACTCCCAGAAG

MOHD ← MOHE → MOHF

TTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCCGGCGGACACAGCCTACATGGAGCTCAGCAGCCTGAGATCTGAGGACACACGGCGGTC

F K S K A T L T V D K S A S T A Y M E L S S L R S E D T A V

F Q G R V T I T V D K S A S T A Y M E L S S L R S E D T A V


TTTCAGGGACGGGTGACAAATCACTGTAGACAAATCCGGCGGACACAGCCTACATGGAGCTCAGCAGCCTGAGATCTGAGGACACACGGCGGTC

—————→ MOHG

TATTA TACTGTGCAAGATCTTTTACTACGGCACGGGGCGTTTGCTTACTGGGGCCAAAGGACTCTGGTCACTGTCTCTTCA
Y Y C A R S F T T A R A F A Y W G Q G T L V T V S S
Y Y C A R S F T T A R A F A Y W G Q G T L V T V S S
TATTA TACTGTGCAAGATCTTTTACTACGGCACGGGGCGTTTGCTTACTGGGGCCAAAGGACTCTGGTCACTGTCTCTTCA


8/18

FIG. 6a




9/18

FIG. 6b




10/18

FIG. 6c




11/18

FIG. 6d




12/18

FIG. 6e




13/18

FIG. 6f




14/18

FIG. 6g




15/18

FIG. 6h



16/18

FIG. 6i



17/18
FIG. 7a





FIG. 7b





18/18
FIG. 7c

FIG. 7d



SEQUENCE LISTING

<110> LG Chemical Limited

<120> Humanized antibody specific for human 4-1BB and pharmaceutical composition comprising same

<130> PC91146/LKY

<150> KR 1998-49177

<151> 1998-11-17

<150> KR 1999-16750

<151> 1999-05-11

<160> 49

<170> KOPATIN 1.5

<210> 1

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Variable region of light chain of humanized antibody Hz4B4-1

<400> 1

Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ala	Thr	Gln	Ser	Val	Ser	Pro	Gly
1				5					10					15	

Glu	Arg	Val	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Thr	Ile	Ser	Asp	Tyr
			20					25					30		

Leu	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ser	Pro	Arg	Leu	Leu	Ile
						35			40				45		

Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile Ser Ser Val Glu Pro
 65 70 75 80

Glu Asp Phe Gly Val Tyr Tyr Cys Gln Asp Gly His Ser Phe Pro Pro
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 2
 <211> 119
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Variable region of heavy chain of humanized antibody Hz4B4-1

<400> 2
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
 20 25 30

Trp Met His Trp Val Lys Gln Ala Pro Gly Gln Val Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr
 65 70 75 80

Ala Arg Ser Phe Thr Thr Ala Arg Ala Phe Ala Tyr Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

$\langle 210 \rangle$	3
$\langle 211 \rangle$	107
$\langle 212 \rangle$	PRT
$\langle 213 \rangle$	Artificial Sequence

<220>
<223> Variable region of light chain of humanized antibody H24B4-2

<400> 3
Asp Ile Val Met Thr Gln Ser Pro Pro Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp Tyr
20 25 30

Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
35 40 45

Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Asp Gly His Ser Phe Pro Pro
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 4
 <211> 119
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Variable region of heavy chain of humanized antibody Hz4B4-2

<400> 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
 20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
 35 40 45

Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Ser Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Ser Phe Thr Thr Ala Arg Ala Phe Ala Tyr Trp Gly Gln Gly
 100 105 110

Thr Leu Val Thr Val Ser Ser
 115

<210> 5
<211> 27
<212> DNA
<213> Artificial Sequence

<220>

<223> primer KXA

<400> 5

actaagcttc atcagacagg cagggga

27

<210> 6
<211> 48
<212> DNA
<213> Artificial Sequence

<220>

<223> primer KXB

<400> 6

tggagacaca gactgggtgg ctggagactg ggatcacaca atgtcccc

48

<210> 7
<211> 48
<212> DNA
<213> Artificial Sequence

<220>

<223> primer KXC

<400> 7

accagctctg tgtctccagg agaaagagtc accctttcct gcagggcc

48

<210> 8

<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> primer KXD

<400> 8

agactggcca ggtttttgtt gataccagtg

30

<210> 9

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> primer KXE

<400> 9

caaaaacctg gccagtctcc aaggcttctc atc

33

<210> 10

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> primer KXF

<400> 10

ttcaggttcc acactgctga tggtagagagt gaaatctgac cc

42

<210> 11

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> primer KXG

<400> 11

agcagtgtgg aacctgaaga ttttgagtg tattactgt

39

<210> 12

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> primer KXH

<400> 12

aggcagatct ttgatttct agcttggt

28

<210> 13

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> primer AMH

<400> 13

attagcggcc gccacatgg gatggagcta tatc

34

<210> 14

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> primer BMH

<400> 14

ttcagcccca gactgcacca gttggacctg gga

33

<210> 15

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> primer CMH

<400> 15

cagtctgggg ctgaagtgt gaagcctggg gct

33

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> primer DMH

<400> 16

tccaggggcc tgcttcaccc agtgcac

27

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> primer EMH

<400> 17

aagcaggccc ctggacaagt ccttgag

27

<210> 18

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> primer FMH

<400> 18

caggctgctg agctccatgt aggctgtgct cgcggatttg tctacagt

48

<210> 19

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> primer GMH

<400> 19

atggagctca gcagcctgag atctgaggac acggcgggtct attactgt

48

<210> 20

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> primer HMH

<400> 20

tatagctagc tgaagagaca gtgaccagag t

31

<210> 21

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> primer HHCD

<400> 21

atatgctagc accaagggcc catcggtc

28

<210> 22

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> primer HKD

<400> 22

atatagatct gtggctgcac catctgtc

28

<210> 23

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer MOKA

<400> 23
ccgctctaga actagagctt c 21

<210> 24
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MOKB

<400> 24
cagagaaagg gttggtggag actgggtcat c 31

<210> 25
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MOKC

<400> 25
accaaccctt tctctgtctc caggagaaag a 31

<210> 26
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MOKD

<400> 26

12

cgctaattgga ctggctggcc ctgca

25

<210> 27

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> primer MOKE

<400> 27

agccagtcca ttagcgacta cttac

25

<210> 28

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> primer MOKF

<400> 28

tggtgagagt gaaatcggtc cctgatccac tgccactgaa cctagcgggg atccc

55

<210> 29

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> primer MOKG

<400> 29

gatttcactc tcaccatcag cagtctggaa cctgaagatt ttgctgtgta ttac

54

<210> 30
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MOKH

<400> 30
aggcagatct ttgatttcc accttggtgc ctccaccg

38

<210> 31
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MOHA

<400> 31
gccgactagt ctgaggccg ccacc

25

<210> 32
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> primer MOHB

<400> 32
actgaagccc caggcttctt cacttcagc

29

<210> 33

<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> primer MOHC

<400> 33

agcctggggc ttcagtgaag gtgtcctgca

30

<210> 34
<211> 33
<212> DNA
<213> Artificial Sequence

<220>

<223> primer MOHD

<400> 34

aaggcgttgt ccaggggcct ggcgcaccca gtg

33

<210> 35
<211> 34
<212> DNA
<213> Artificial Sequence

<220>

<223> primer MOHE

<400> 35

ccctggacaa cgccttgagt ggatgggaga gatt

34

<210> 36
<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer MOHF

<400> 36

acgcgtccct ggaacttctg ggagtagtta gtatgaccgt t

41

<210> 37

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer MOHG

<400> 37

agttccaggg acgcgtgaca atcactgtag acaaatccgc g

41

<210> 38

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Variable region of light chain of mouse monoclonal antibody 4B4-1-1

<400> 38

Asp Ile Val Met Thr Gln Ser Gln Ala Thr Gln Ser Val Thr Pro Gly
1 5 10 15

Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Thr Ile Ser Asp Tyr
20 25 30

16

Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
 35 40 45

Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Pro
 65 70 75 80

Glu Asp Val Gly Val Tyr Tyr Cys Gln Asp Gly His Ser Phe Pro Pro
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 39

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> Variable region of heavy chain of mouse monoclonal antibody 4B4-1-1

<400> 39

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
 20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Val Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn Pro Gly Asn Gly His Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

17

Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Ser Phe Thr Thr Ala Arg Ala Phe Ala Tyr Trp Gly Gln Gly
 100 105 110

Thr Leu Val Thr Val Ser Ala
 115

<210> 40
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Variable region of light chain of human antibody (X82934)

<400> 40
 Asp Val Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Arg Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210>	41
<211>	119
<212>	PRT
<213>	Artificial Sequence

<220>
<223> Variable region of heavy chain of human antibody (M17750)

<400> 41
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
35 40 45

Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Tyr Tyr Gly Ser Gly Ser Asn Tyr Trp Gly Glu Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 42
<211> 415
<212> DNA
<213> Artificial Sequence

<220>

<223> Gene coding for the variable region of light chain of humanized antibody Hz4B4-1

<400> 42
actagagctt catcacacag gcaggggaag caagatggat tcacaggccc aggttcttat 60
gttactgctg ctatgggtat ctggtacctg tggggacatt gtgatgacct agtctccagc 120
caccagctct gtgtctccag gagaaagagt caccctttcc tgcagggccca gccagactat 180
tagcgactac ttacactggt atcaacaaaa acctggccag tctccaaggc ttctcatcaa 240
atatgttccc caatccatct ctgggatccc ctccagggtc agtggcagtg gatcagggtc 300
agatttcact ctccaccatca gcagtgtgga acctgaagat tttggagtgt attactgtca 360
agatggtcac agctttcctc cgacgttcgg tggaggcacc aagctagaaa tcaaa 415

<210> 43
<211> 423
<212> DNA
<213> Artificial Sequence

<220>

<223> Gene coding for variable region of heavy chain of humanized antibody Hz4B4-1

<400> 43
 gccgccacca tgggaaggag ctatatcacc ctctttttgg tagcaacagc tacagatgtc 60
 cactcccagg tccaactggg gcagtctggg gctgaagtgg tgaagcctgg ggcttcagtg 120
 aagctgtcct gcaaggcttc tggctacacc ttcagcagct actggatgca ctgggtgaag 180
 caggcccctg gacaagtcct tgagtggatt ggagagatta atcctggcaa cggtcatact 240
 aactacaatg agaagttcaa gagcaaggcc aactgactg tagacaaatc cgcgagcaca 300
 gcctacatgg agctcagcag cctgagatct gaggacacgg cggctctatta ctgtgcaaga 360
 tcttttacta cggcacgggc gtitgcttac tggggccaag ggactctggt cactgtctct 420
 tca 423

<210> 44
 <211> 415
 <212> DNA
 <213> Artificial Sequence

<220>

<223> gene coding for variable region of light chain of mouse monoclonal antibody 4B4-1-1

<400> 44
 actagagctt catcagacag gcaggggaag caagatggat tcacaggccc aggttcttat 60
 gttactgctg ctatgggtat ctggtacctg tggggacatt gtgatgacct agtctcaagc 120
 caccagctct gtgactccag gagatagagt ctctctttcc tgcagggcca gccagactat 180
 tagcgactac ttacactggg atcaacaaaa atcacatgag tctccaaggc ttctcatcaa 240
 atatgcttcc caatccatct ctgggatccc ctccaggttc agtggcagtg gatcagggtc 300

agatttcact ctcagtatca acagtgtgga acctgaagat gttggagtgt attactgtca 360

agatggtcac agctttcctc cgacgttcgg tggaggcacc aagctagaaa tcaaa 415

<210> 45

<211> 423

<212> DNA

<213> Artificial Sequence

<220>

<223> gene coding for variable region of heavy chain of mouse monoclonal antibody 4B4-1-1

<400> 45

gccgccacca tgggatggag ctatatcatc ctctttttgg tagcaacagc tacagatgtc 60

cactcccagg tccaactgca gcagcctggg gctgaactgg tgaagcctgg ggcttcagtg 120

aagctgtcct gcaaggcttc tggctacacc ttcagcagct actggatgca ctgggtgaag 180

cagaggcctg gacaagtcct tgagtggatt ggagagatta atcctggcaa cggtcatact 240

aactacaatg agaagttcaa gagcaaggcc aactgactg tagacaaatc ctccagcaca 300

gcctacatgc aactcagcag cctgacatct gaggactctg cggtctatta ctgtgcaaga 360

tcttttacta cggcacgggc gtttgcttac tggggccaag ggactctggt cactgtctct 420

gca 423

<210> 46

<211> 415

<212> DNA

<213> Artificial Sequence

<220>

<223> gene coding for variable region of light chain of humanized antibody Hz4B4-2

<400> 46

```
actagagctt catcagacag gcagggaag caagatggat tcacaggccc aggttcttat      60
gttactgctg ctatgggtat ctggtacctg tggggacatt gtgatgaccc agtctccacc    120
aaccctttct ctgtctccag gagaaagagt caccctttcc tgcagggccca gccagtcctat    180
tagcgactac ttacactggg atcaacaaaa acctggccag tctccaaggc ttctcatcaa      240
atatgcttcc caatccatct ctgggatccc cgctaggttc agtggcagtg gatcaggacg      300
cgatttcact ctcaccatca gcagtctgga acctgaagat tttgctgtgt attactgtca      360
agatggtcac agctttcttc cgacgttcgg tggaggcacc aaggtggaaa tcaaa          415
```

<210> 47

<211> 423

<212> DNA

<213> Artificial Sequence

<220>

<223> gene coding for variable region of heavy chain of humanized antibody Hz4B4-2

<400> 47

```
gccgccacca tgggatggag ctatatcacc ctctttttgg tagcaacagc tacagatgtc      60
cactcccagg tccaactggg gcagtctggg gctgaagtga agaagcctgg ggcttcagtg    120
aaggtgtcct gcaaggttcc tggctacacc ttcagcagct actggatgca ctgggtgcgc      180
caggccccctg gacaacgcct tgagtggatg ggagagatta atcctggcaa cggtcatact    240
```

aactactccc agaagttcca gggacgcgtg acaatcactg tagacaaatc cgcgagcaca 300
gcctacatgg agctcagcag cctgagatct gaggacacgg cggctctatta ctgtgcaaga 360
tcttttacta cggcacgggc gtttgcttac tggggccaag ggactctggt cactgtctct 420
tca 423

<210> 48
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> primer Ryu-93

<400> 48
gaagtcgacc taacactctc ccctgtt 27

<210> 49
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> primer Ryu-101

<400> 49
cggtcgactc atttaccgg agacag 26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00689

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C 07 K 16/28; A 61 K 39/395, C 12 N 15/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C 07 K; A 61 K, C 12 N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL DATABASE, Derwent Publications Ltd., London (GB), PAJ DATABASE, EPO PAJ Database, CA DATABASE, STN Karlsruhe (DE)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 98/16249 A1 (BRISTOL-MYERS SQUIBB COMPANY) 23 April 1998 (23.04.98), pages 4-11; claims	1-6,11,25,27-32 7-10,12-24,26
A	W.W. SHUFORD et al. "4-1BB Costimulatory Signals Preferentially Induce CD8 ⁺ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses", The Journal of Experimental Medicine, Vol. 186, No. 1, 07 July 1997 (07.07.97), pages 47-55, totality.	1-32
A	WO 96/29348 A1 (INDIANA UNIVERSITY FOUNDATION), 26 September 1996 (26.09.96), abstract; claims.	1-32

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„I“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

26 January 2000 (26.01.00)

Date of mailing of the international search report

29 March 2000 (29.03.00)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/200

Authorized officer

Weniger

Telephone No. 1/53424/341

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 99/00689

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 25 and 27, please see remark
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 25 and 27 are directed to a method of treatment of the human or animal body by therapy (rule 39.1(iv) PCT) the Search Report has been established for these claims, as well, and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR 99/00689

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
GB	A1	2085694	28-04-1982	none	
GB	B2	2085694	01-02-1984		
DE	A1	2733580	08-02-1979	none	